Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BON NASDAQ:PTPI NASDAQ:SYRS NASDAQ:TRVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.41-3.4%$1.52$1.14▼$73.75$235K-0.491.12 million shs100,623 shsPTPIPetros Pharmaceuticals$0.03$0.05$0.02▼$16.25$897K1.563.18 million shs273,354 shsSYRSSyros Pharmaceuticals$0.01-1.0%$0.02$0.00▼$6.93$1.65M1.318.09 million shs17,423 shsTRVNTrevena$0.91$1.06$0.73▼$7.85$873K0.612,072 shs8 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life0.00%-4.73%+2.92%-1.74%-97.45%PTPIPetros Pharmaceuticals0.00%+1.05%+6.67%-97.19%-99.73%SYRSSyros Pharmaceuticals0.00%-0.99%-64.54%-62.83%-99.85%TRVNTrevena0.00%-2.69%-20.18%-18.75%-84.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBONBon Natural LifeN/AN/AN/AN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals4.136 of 5 stars3.14.00.04.31.12.50.6TRVNTrevena1.2273 of 5 stars3.03.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/ASYRSSyros Pharmaceuticals 2.20Hold$3.3333,233.33% UpsideTRVNTrevena 2.00Hold$5.00449.45% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$23.84M0.01$1.81 per share0.78$37.78 per share0.04PTPIPetros Pharmaceuticals$5.11M0.18N/AN/A$4.04 per share0.01SYRSSyros Pharmaceuticals$386K0.70N/AN/A$0.79 per share0.01TRVNTrevena$443K1.97N/AN/A($11.07) per share-0.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/APTPIPetros Pharmaceuticals-$8.16M-$60.87N/A∞N/AN/A-78.22%-23.50%N/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)TRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)Latest BON, TRVN, PTPI, and SYRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.022.422.32PTPIPetros Pharmaceuticals1.580.850.74SYRSSyros PharmaceuticalsN/A2.252.25TRVNTrevenaN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%PTPIPetros Pharmaceuticals12.34%SYRSSyros Pharmaceuticals91.47%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%PTPIPetros Pharmaceuticals12.25%SYRSSyros Pharmaceuticals12.26%TRVNTrevena2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life100167,000863,000Not OptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionOptionableTRVNTrevena40959,000841,000OptionableBON, TRVN, PTPI, and SYRS HeadlinesRecent News About These CompaniesSoftball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honoredJuly 8, 2025 | msn.comTrevena, Inc. (TRVN) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comTrevena Enters Securities Exchange Agreement with InvestorMay 15, 2025 | tipranks.comBerks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball winApril 11, 2025 | readingeagle.comRVanessa Hudgens and Oliver Trevena Appear at Expo West for CaliwaterMarch 9, 2025 | msn.comJMP Securities downgrades Trevena (TRVN) to a HoldDecember 27, 2024 | markets.businessinsider.com‘Plane’ Actor Oliver Trevena Signs With Untitled EntertainmentDecember 16, 2024 | yahoo.comLyme Regis town councillor John Trevena stand downDecember 11, 2024 | bridportnews.co.ukBTrevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowDecember 10, 2024 | zacks.comTrevena appoints new financial chiefNovember 29, 2024 | investing.comTrevena Appoints Katrine Sutton as New CFONovember 27, 2024 | tipranks.comHC Wainwright & Co. Downgrades Trevena (TRVN)November 16, 2024 | msn.comTrevena, Inc. Navigates Financial Challenges and Strategic ChangesNovember 9, 2024 | msn.comChester County biopharm firm's latest layoffs impact its C-suiteNovember 7, 2024 | bizjournals.comTrevena teeters in dangerous territory, terminating CEO and other execs amid strategic reviewNovember 7, 2024 | fiercebiotech.comFTrevena Reports Third Quarter 2024 Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comWhy Trevena (TRVN) Stock Is Down 43% TodayOctober 8, 2024 | msn.comTrevena, Inc. Faces Delisting from NasdaqOctober 6, 2024 | msn.comTrevena Announces Receipt of Nasdaq Delisting NotificationOctober 4, 2024 | globenewswire.comLearn to Evaluate (TRVN) using the ChartsSeptember 16, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeSuper Micro’s Bold $2B Bond Plan Signals 35% Premium UpsideBy Gabriel Osorio-Mazilli | June 26, 2025View Super Micro’s Bold $2B Bond Plan Signals 35% Premium UpsideWhy Occidental's Price Dip Signals a Buying OpportunityBy Jeffrey Neal Johnson | July 3, 2025View Why Occidental's Price Dip Signals a Buying OpportunityBON, TRVN, PTPI, and SYRS Company DescriptionsBon Natural Life NYSE:BON$1.41 -0.05 (-3.42%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.40 0.00 (-0.35%) As of 07/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Petros Pharmaceuticals NASDAQ:PTPI$0.03 0.00 (0.00%) As of 07/18/2025 03:41 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Syros Pharmaceuticals NASDAQ:SYRS$0.01 0.00 (-0.99%) As of 07/18/2025 03:54 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Trevena NASDAQ:TRVN$0.91 0.00 (0.00%) As of 07/18/2025Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
